{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.7"},{"groupId":"OG001","value":"11.6"},{"groupId":"OG002","value":"13.8"}]}],"title":"Progressed to AP-CML"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2"},{"groupId":"OG001","value":"1.1"},{"groupId":"OG002","value":"2.1"}]}],"title":"Progressed to BP-CML"}],"denoms":[{"counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"95"},{"groupId":"OG002","value":"94"}],"units":"Participants"}],"description":"Progression to AP is defined as: \\>=15% and \\<30% blasts in peripheral blood or bone marrow or \\>=20% basophils in peripheral blood or bone marrow or \\>=30% blasts + promyelocytes in peripheral blood or bone marrow (but \\<30% blasts) or \\<100\\*109 platelets/L in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to BP is defined as: \\>=30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly.","groups":[{"description":"Participants received ponatinib 45 mg orally once daily in each 28-day cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.","id":"OG000","title":"Treatment Period: Cohort A: Ponatinib 45 mg"},{"description":"Participants received ponatinib 30 mg orally once daily in each 28-day cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.","id":"OG001","title":"Treatment Period: Cohort B: Ponatinib 30 mg"},{"description":"Participants received ponatinib 15 mg orally once daily in each 28-day cycle.","id":"OG002","title":"Treatment Period: Cohort C: Ponatinib 15 mg"}],"paramType":"NUMBER","populationDescription":"All randomized participants were included in the analysis.","reportingStatus":"POSTED","timeFrame":"From first dose date of study treatment up to approximately 8.9 years","title":"Percentage of Participants With Progression to Accelerated Phase (AP)-Chronic Myeloid Leukemia (CML) or Blast Phase (BP)-CML","type":"SECONDARY","unitOfMeasure":"percentage of participants"}